New program aims to protect HIV patients from HPV cancer

NCT ID NCT05065840

Ongoing Prevention Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a program to help HIV-positive adults get the HPV vaccine, which can prevent HPV-related cancers. The program gives clinics and staff tools to encourage vaccination. Researchers will track how many people start and finish the vaccine series over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CDC 4 Pillars Program (a behavioral intervention to increase vaccination uptake)
What this could lead to: If successful, this program could become a model for boosting HPV vaccination rates in high-risk HIV populations, potentially reducing HPV-related cancers.
What could go wrong: This is an implementation study, not a test of the vaccine itself. Success depends on clinics and patients following through, and results may not apply to other regions or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN PAPILLOMA VIRUS HUMAN PAPILLOMA VIRUS VACCINE

Contacts and locations

Locations

AHF Lithonia

Lithonia, Georgia, 30058, United States
AID Atlanta

Atlanta, Georgia, 30309, United States
Albany Rural Model Clinic

Albany, Georgia, 31705, United States
Faebris

Atlanta, Georgia, 30311, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.